dolasetron and aprepitant

dolasetron has been researched along with aprepitant in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Ahmed, T; Li, SX; Lupinacci, P; Majumdar, A; Murphy, MG; Panebianco, D; Pequignot, E; Petty, KJ; Rosen, L; Royalty, JE; Rushmore, TH1
Wilkes, G1

Reviews

1 review(s) available for dolasetron and aprepitant

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for dolasetron and aprepitant

ArticleYear
Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers.
    Journal of clinical pharmacology, 2006, Volume: 46, Issue:7

    Topics: Administration, Oral; Adult; Antiemetics; Aprepitant; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Electrocardiography; Enzyme Inhibitors; Female; Genotype; Humans; Indoles; Male; Middle Aged; Morpholines; Quinolizines; Reference Values; Serotonin Antagonists

2006

Other Studies

2 other study(ies) available for dolasetron and aprepitant

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Antiemetic agents.
    Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:8 Suppl

    Topics: Administration, Oral; Anorexia; Antiemetics; Antineoplastic Agents; Aprepitant; Asthenia; Constipation; Diarrhea; Drug Interactions; Dyspepsia; Fatigue; Fever; Granisetron; Headache; Hiccup; Humans; Indoles; Injections, Intravenous; Isoquinolines; Morpholines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Vomiting

2007